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Sodium ozagrel (SO) prevents platelet aggregation and vasoconstriction in the cerebral ischemia. It plays an important role in
the prevention of brain damage induced by cerebral ischemia/reperfusion. Recently, many animal studies have suggested that
the Panax ginseng (PG) has neuroprotective eﬀects in the ischemic brain. In this study, we assessed the neuroprotective eﬀects
that come from a combination therapy of SO and PG in rat models with middle cerebral artery occlusion (MCAO). Animals
with MCAO were assigned randomly to one of the following four groups: (1) control (Con) group, (2) SO group (3mg/kg,
intravenously), (3) PG group (200mg/kg, oral feeding), and (4) SO + PG group. The rats were subjected to a neurobehavior
test including adhesive removal test and rotarod test at 1, 3, 7, 10, and 15 days after MCAO. The cerebral ischemic volume
was quantiﬁed by Metamorph imaging software after 2-3-5-triphenyltetrazolium (TTC) staining. The neuronal cell survival and
astrocytes expansion were assessed by immunohistoﬂuorescence staining. In the adhesive removal test, the rats of PG or SO +
PG group showed signiﬁcantly better performance than those of the control group (Con: 88.1 ± 24.8, PG: 43.6 ± 11, SO + PG:
11.8 ± 7, P<. 05). Notably, the combination therapy group (SO + PG) showed better performance than the SO group alone (SO:
56 ± 12, SO + PG: 11.8 ± 7, P<. 05). In TTC staining for infarct volume, cerebral ischemic areas were also signiﬁcantly reduced
in the PG group and SO + PG group (Con: 219 ±32, PG: 117 ±8, SO + PG: 99 ±11, P<. 05). Immunohistoﬂuorescencestaining
results showed that the group which received SO + PG group therapy had neuron cells in the normal range. They also had a low
number of astrocytes and apoptotic cells compared with the control or SO group in the peri-infarction area. During astrocytes
staining,compared to the SO + PG group, the PG group showed only minordiﬀerences in the number of NeuN-positive cells and
quantitative analysis of infarct volume. In conclusion, these studies showed that in MCAO rat models, the combination therapy
with SO and PG may provide better neuroprotective eﬀects such as higher neuronal cell survival and inhibition of astrocytes
expansion than monotherapy with SO alone.
1.Introduction
Acute ischemic stroke is one of the leading causes of adult
disability and death in the world, with an incidence aﬀecting
up to 0.2% of the population every year [1]. Neuronal
cell injury, including apoptosis, is the major event in the
acute and subacute phase of cerebral ischemia, where the
formation of a glial scar resulting from reactive gliosis
(mainly consisting of proliferated astrocytes) is detected in
t h el a t ep h a s e[ 2, 3]. Reactive gliosis plays the role of a
biochemical and physical barrier for regeneration of the
axon [2]. Although the exact mechanism of neurological
destruction of the brain caused by cerebral ischemia has
not been elucidated yet, studies suggest that oxidative stress,
inﬂammatory cytokines, and excitotoxicity may play a role
[4, 5].
Many researchers suggested that these mechanisms de-
struct the neuronal cells and induce the vasoconstriction of2 Journal of Biomedicine and Biotechnology
cerebral artery. Platelet aggregation was also reported as one
of the aggravating factors of cerebral ischemia. The role
of thromboxane A2 (TXA2), a strong vasoconstrictor and
platelet aggregator, was well established by several studies
as an example, [6–9]. Sodium ozagrel (SO), a selective
TXA2 synthetase inhibitor, showed a suppressive eﬀect on
vasospasm and platelet aggregation in animal and human
experiments [8, 9].
Traditionally, the root of Panax ginseng (PG) has been
widely used as a herbal medicine to treat diverse diseases
including some neurological disorders in Korea. Yoshikawa
and his colleague reported that PG improves neurological
dysfunction and prevents histological injury such as pro-
liferation of astrocyte and apoptosis of neuronal cells in
the ischemic brain [10]. Also, some researchers showed
decrease in the infarct volume after administration of PG
extract in the cerebral ischemic rat model [11, 12]. They
suggested that the roots of PG have a neuroprotective
eﬀect in the ischemic brain, caused by inﬂammation inhi-
bition and microglial activation. These anti-inﬂammation,
antioxidation, antithrombotic, and antiapoptotic eﬀects on
neuronal cells prompt us to test eﬀects of PG extract on
the recovery from cerebral ischemia. These days, it has
become a very common practice to take herbal medicine. In
the United States, nearly 1 in 6 adults concomitantly take
at least one herbal remedy with their prescription drugs
[13]. Recently, many western studies have started trying
combination therapy with herbal medicine especially for
cerebral ischemia.
In this study, we assessed whether the combination
therapy of SO and PG shows synergistic or additive eﬀect
in the recovery of cerebral ischemia by performing a
neurobehavioral test and histological observation on infarct
areas.
2.Materialsand Methods
2.1. Preparation of SO and Administration to Rats. SO(Kissei
Pharmaceutical Co. Ltd., Matsumoto, Japan), 4mg/ml, was
prepared by dissolving in 0.9% saline. SO was injected intra-
venously to the tail vein within 30min after the reperfusion
in the middle cerebral artery occlusion (MCAO) rat models.
Rats were treated with SO solution (3mg/kg) everyday for a
week [7].
2.2. Preparation of PG Extracts and Administration to Rats.
Dried roots of PG were obtained from the National Institute
ofCropScienceandidentiﬁedbyDr.Kim,Ginseng &Medic-
inalCropsDivision,NationalInstituteofCropScience,Rural
Development Administration (Suwon, Republic of Korea).
Powdered extracts of PG were made as described by Kim
et al. [14]. Dried roots of PG (1.0kg) were extracted with
70% ethanol under sonication. The 70% ethanol ﬁltrate
was evaporated in vacuo to give ethanol extracts (238g),
which were then stored at −20◦C until use. The powdered
extracts of PG were dissolved in saline to obtain a solution of
200mg/mL. Animals were fed the same doses of PG through
the oral zonde needle within 30min after the reperfusion in
the rat models (200mg/kg) [14]. Rats were treated everyday
for a week with PG extracts.
2.3. Ischemic Animal Model. All animal procedures were
carried out in accordance with the animal experimental
guideline established by the Institutional Animal Care and
Use Committee of Catholic University Medical School.
Transient MCAO was induced as described by Longa et al.,
[15] with a minor modiﬁcations. Male Sprague-Dawley rats
(270–305g) were brieﬂy anesthetized with 5% isoﬂurane
in oxygen/nitrogen (N2O/O2 [30/70]). During a surgical
procedure, a mixture of 2% isoﬂurane and N2O/O2 (30/70)
was used to maintain anesthesia. Rectal temperature was
maintained at (37 ± 5◦C) using a rectal thermometer and
a heating pad (Harvard Apparatus Inc., Holliston, Mas-
sachusetts, USA). The right common carotid artery (CCA),
external carotid artery (ECA), and internal carotid artery
(ICA) were exposed through a ventral midline incision. A
3–0 monoﬁlament nylon suture with a rounded tip was
introducedintotheCCAlumenandgentlyadvancedintothe
ICA until it blocked the bifurcating origin of the MCA.
Cortical blood ﬂow was measured continuously with a
laser Doppler (Transonic system Inc., Ithaca, NY, USA) in
anesthetized animals. A photodetector probe (0.45mm in
diameter) was stereotaxically placed through a skull burr
hole (1mm diameter) in the frontoparietal cortex (1.3mm
posterior, 2.8mm lateral to the bregma, and 1.0mm above
the dura). Ninety minutes after the occlusion, animals
were reanesthetized and reperfused by withdrawing the
suture until the tip cleared the lumen of CCA. Regional
cerebral blood ﬂow (rCBF) was expressed as a percentage
of preischemic baseline values. MCAO animals were only
included if occlusion caused a decrease in rCBF to 30% of
the original blood ﬂow.
2.4. Experimental Groups. Animals were assigned randomly
to one of the following four groups: (1) the ﬁrst group ofrats
were treated with saline as the control group (n = 5, Con
group), (2) the second group was injected with SO (n = 5,
SO group), (3) the third group was fed with PG (n = 5, PG
group), and (4) the fourth group was treated with SO plus
PG (n = 5, SO + PG group).
2.5. Behavior Evaluation. Behavior parameters were evalu-
ated with adhesive removal and rotarod test at 1, 3, 7, 10,
and 15 days after MCAO.
2.6. Adhesive Removal Test. Square dots of adhesive-backed
paper (12φ) were used as bilateral tactile stimuli occupying
the distal-radial region on the wrist of each forelimb.
Animals were given three trials with a cut-oﬀ time of 180
seconds. The data are presented at the mean time to remove
the left dot.
2.7. Rota-Rod test. In the Rota-rod motor test, Animals were
pretrained three times for a week before MCAO. The Rota-
rod cylinder was accelerated from 4 to 40rpm within 5
minutes, and the cutoﬀ time was 300 seconds.Journal of Biomedicine and Biotechnology 3
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Figure 1: These ﬁgures show the cerebral ischemic area at 15 days after MCAO rats. ((a) control group: Con, (b) Sodium Ozagrel group:
SO, (c) Panax ginseng group: PG, (d) Sodium Ozagrel plus Panax ginseng group: SO + PG). The ischemic areas were identiﬁed by 2%
2-3-5-triphenylterazolium staining; nonstained areas are ischemic areas. (e) Calculated infarct volumes based on 6 sequential brain slices.
Treatment withPGorSO+PGgroup showedsigniﬁcantreduction ininfarctvolume,andSO+PGgroup showedmuch reduction ofinfarct
volume compared to other groups. ∗P<. 05.
2.8.DeterminationofInfarct Volume. At15daysafterMCAO,
all rats (n = 5, for each group) were deeply anesthetized
with 15% urethane and sacriﬁced by decapitation. Then the
brain was immediately removed and sectioned into 2 equally
spaced (2mm) coronal blocks using a rodent brain matrix.
These sections were stained by 0.1M PBS containing 2% 2-
3-5-triphenylterazolium (TTC; Sigma, St. Louis, MO, USA)
for15minutesat37◦C.UsingMeta-Morphimagingprogram
(MolecularDevicesInc,Downingtown, PA,USA),theinfarct
area was determined by using the method of subtracting the
area of the noninfarct ipsilateral hemisphere from that of the
contralateral tissue to reduce errors that might occur due to
cerebral edema.
2.9. Immunohistochemical Staining. T h et i s s u ew a sc u tc o r o -
nally at a thickness of 4μm between +0.1−0.86mm of
the boundary area of cerebral infarct in the precentral
gyrus, located 24-mm posterior to the frontal pole from
each rat for a total of three blocks. The sections were
warmed for 20 minutes and washed with 0.01M PBS
for 10 minutes. Sections were blocked in normal goat
serum for 1 hour at room temperature. The sections
were incubated with mouse antibody to NeuN (Neuronal
Nuclei, Millipore, Inc., diluted at 1:100) and GFAP (Glial
ﬁbrillary acidic protein, Millipore, Inc., diluted at 1:200)
o v e r n i g h ta t4 ◦C. Subsequently, sections were incubated for
1hr at room temperature with Alexa 488-conjugated goat
antimouse IgG (Vector Laboratories, 1:200). After washing,
the sections were counterstained and stored at −20◦C
and then observed under both a ﬂuorescence microscope
equipped with a spot digital camera and a confocal scanning
laser microscope (LSM 510, Zeiss, Germany). Apoptosis
was detected by the terminal deoxynucleotidyl transferase-
mediated d-UTP-biotin nick end (TUNEL) assay by means
of the in situ cell death detection kit (Rochcce, Indianapolis,
IN, USA) developed using the Cy2-conjugated streptavidin
(Jackson Laboratories, West Grove, PA). The slides were
observedbyconfocalscanninglasermicroscope.UsingMeta-
Morph imaging program (Molecular Devices Inc, Down-
ingtown, PA, USA), ischemic penumbra was determined by
optical density of GFAP and TUNEL and NeuN positive
cells.
2.10. Statistical Analysis. The behavior tests, cerebral
ischemic volume, tissue density of astrocyte, cell count of
NeuN-positive cells, and cell count of apoptotic cells were
subjected to the Kruskall-Wallis test and Mann-Whitney
U test for each group of rats. Data are presented as mean
values ± standard error. Value of P<. 05 were considered
statistically signiﬁcant.4 Journal of Biomedicine and Biotechnology
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Figure 2: Behavior test at 15 days after stroke. Adhesive removal
test (a) and rotarod test (b) at 1, 3, 7, 10, and 15 days after
middle cerebral artery occlusion (MCAO). The group which
received combined therapy of SO and PG scored best behavioral
performance in both the adhesive removal test and rota-rod test.
∗P<. 05.
3.Results
3.1. Induction of Transient Cerebral Ischemia Using Laser
Doppler. Cortical bloodﬂow measured using a laser-doppler
ﬂowmetry (LDF) decreased after MCAO by at least 70% in
all animals. After insertion of the intraluminal ﬁlament, the
mean rCBF (regional cerebral blood ﬂow) decreased to less
than 24.5% of the preocclusion value (before MCAO: 63.5 ±
15.4 ml/100g/min, MCAO: 15.6 ± 5.16ml/100g/min).
Immediately afterreperfusion, the LDFreading wasreturned
to slightly less than baseline.
3.2. Infarct Volume. The neuroprotective eﬀects of the SO +
PG therapy were evaluated by measuring infarct volumes
1 5d a y sa f t e rM C A O .T h eb r a i n so fr a t sw e r es t a i n e dw i t h
TTC to obtain infarct volume and calculated by measuring
the area of infarction area. Drug-induced hemorrhagic com-
plication was not seen in the rats. Figures 1(a)–1(d) shows
typical photographs of TTC-stained sections of treatment
and control groups. As seen in Figure 1(e), the infarct
volumes of all treatment groups were grossly decreased
compared with a control group. But, there were signiﬁcant
diﬀerences between control groups and PG group or SO +
PG group, and also between SO and SO + PG group (Con:
219 ± 32,SO:142 ± 14,PG: 117 ±8, SO+PG: 99 ± 11mm3,
P<. 05).
3.3.Behavior Analysis. We evaluated the eﬀectsoftreatments
on the recovery of behavioral functions using adhesive
removal and rota-rod test (Figure 2). Prior to MCAO,
neurological scores were similar among all groups. As shown
in Figure 2(a), PG group and combination therapy with SO
and PG group showed signiﬁcantly improved performance
than control group on adhesive removal test (Con: 88.1 ±
24.8, PG: 43.6 ± 11, SO + PG: 11.8 ± 7s e c o n d s ,P<
.05). Between SO and PG groups, there was no signiﬁcant
diﬀerence in the score of adhesive removal test (SO: 56 ±
12 seconds, PG: 43.6 ± 11, P<. 05). Additionally, the
group treated with combination of SO and PG showed
signiﬁcantly better score than the group treated with SO
alone (SO: 56 ± 12, SO + PG: 11.8 ± 7s e c o n d s ,P<
.05). To evaluate coordination, balance, and motor function,
rats were subjected to rota-rod test. Only the group treated
with combination of SO and PG signiﬁcantly showed better
performance than control group on the results at 3 days
(Con: 6 ± 1, SO + PG: 95 ± 15 seconds, P<. 05). These
resultsshowthatthegroupwithcombinedtherapyofSOand
PG had the best recovery from MCAO.
3.4. Activating Astrocyte, Neuronal Death, and Apoptotic Cell
Death. We observed the number of astrocytes, neurons, and
apoptotic cells at 15 days after MCAO in the peri-infarct
regions. On analysis of GFAP positive cells, all drug-treated
groups showed signiﬁcant decrease in the density of GFAP
positive cells compared to the control group (Con: 1455 ±
150, SO: 1085 ± 121, PG: 955 ± 92, SO + PG: 778 ± 87
optical density, P<. 05) (Figure 3). There was no diﬀerence
between SO- and PG-treated groups (SO: 1085 ± 121, PG:
955 ± 92 optical density, P<. 05). However, the group
treated with combination of SO and PG showed signiﬁcantly
lower astrocyte density compared to the group which was
treated with SO or PG alone (SO: 1085 ± 121, PG: 955 ±
92, SO + PG: 778 ± 87 optical density, P<. 05). This result
indicates that SO and PG may protect against the delayed
infarct expansion through secondary oxidative injury caused
by activated astrocytes.
Apoptoticcells were recognized by identiﬁcation of DNA
fragmentation using the terminal deoxynucleotidyl trans-
ferase mediated UTP nick end labeling (TUNEL) method.
All treated groups had reduced TUNEL-positive cells as
compared with control group. Also, the groups treated with
combination of SO and PG showed signiﬁcantly decreased
number of TUNEL-positive cells compared with controlJournal of Biomedicine and Biotechnology 5
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Figure 3: Quantitative analysis of immunoreactivities of GFAP at 15 days after MCAO. Histological analysis of Con (a), SO (b), PG (c),
and SO + PG (d) was shown into GFAP staining at 15 days after MCAO. Quantitative immunoreactivities for all four groups are shown as
bar graphs on the right side of each panel (e). The expression of GFAP in SO + PG group was signiﬁcantly decreased compared with other
groups. ∗P<. 05.
group or SO alone (Con: 243 ± 36, PG: 135 ± 10, SO +
PG: 114 ± 8 cells/mm2, P<. 05). However, treatment with
SO alone did not show signiﬁcant decrease in the TUNEL
positive cells compared to control group (Con: 243 ± 36,
SO: 196 ± 29, PG: 135 ± 10cells/mm2, P<. 05) (Figure 4).
In an inverse study of TUNEL stain, all drug-treated groups
showed higher number of NeuN-positive cells compared
to control group (Con: 36 ± 9, SO: 70 ± 7, PG: 101 ±
8, SO + PG: 132 ± 23 cells/mm2, P<. 05) (Figure 5).
The group treated with combination of SO and PG showed
signiﬁcantly highernumber ofNeuNpositive cellscompared
to the SO treated group (SO: 70 ± 7, SO + PG: 132 ±
23 cells/mm2, P<. 05). These results suggest that SO +
PG group eﬀectively prevents expansion of astrocyte and
apoptotic neuronal death in MCAO model.
4.Discussion
This study showed for the ﬁrst time that the combi-
nation therapy is superior to monotherapy of SO or
PG in poststroke therapy, as evidence by neurobehavioral
tests and histological examination. Recently, PG has been
applied as treatment for many neurologic disorders [16].
Especially, the eﬀects of free radical scavenger and anti-
inﬂammatory functions have been reported to play a role
of neuroprotection [12, 17, 18]. Ye et al., [19]r e p o r t e d
that the ginsengs have neuroprotection eﬀects on animals
with cerebral infraction which have insulted by glucose-
oxygen deﬁciency. Kim et al., [14] reported similar results in
global ischemic rat models. Recently, Yoshikawa et al., [10]
have reported that ginseng have reduced the neurodegen-
eration around the cerebral infraction areas. In this present
study, all drug-treatment groups showed improvement of
behavioral disability than control group using the adhesive
removal test. Especially, SO + PG group showed signiﬁcant
improvement of behavioral disability in both the rotarod
test and adhesive removal test. These behavioral assessment
results of SO + PG group were outstanding compared to
the control group and monotherapy with SO. They suggest
that PG attributes to the improvement of neurobehavioral
disability in the MCAO rats. These results are similar
with what prior researchers have studied [10]. Yoshikawa
et al. [10] showed that ginsenoside Rb1, which is a major
ingredient of PG, protects the neurological dysfunctions
and improve the neurologic score in cerebral ischemic
animals.
According to the reports, the ischemic area markedly
reduced after treatment of PG [11, 12]. Son et al., [12]
showed decreasein infarction volumeafter administration of
PG extract in MCAO rat models. They suggest that the roots6 Journal of Biomedicine and Biotechnology
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Figure 4:QuantitativeanalysisoftheTUNEL stainingforidentifyingapoptoticcells.Apoptotic cells were identiﬁedby immunoﬂuorescence
FITC (green; (b), (e), (h), (k)) and DAPI (blue; (a), (d), (g), (j)). TUNEL positive cells were counted using Meta-Morph program (c), (f),
(i), (l).(m) shows the quantitative data for TUNEL positive cells. The SO + PG group was signiﬁcantly decreased compared to Con and PG.
∗P<. 05.
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Figure 5: Quantitative analysis of NeuN-positive cell. These ﬁgures show the NeuN positive cells on peri-infarct area in Con group (a), SO
group(b),PGgroup(c),andSOplusPGgroup (d)at15daysafterMCAO.The number ofNeuN positive cells inthisarea showedsigniﬁcant
diﬀerence between control group and all treated groups. The number of these cells decreased very much in the control group. There were
many NeuN-positive cells in SO + PG group compared to other groups. However, there was no diﬀerence between PG and SO + PG group.
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of PG have a neuroprotective eﬀect in the ischemic brain.
Due to the inhibition of inﬂammation and of microglial
activation, it can be used as a potential therapeutic agent
against inﬂammation in ischemic stroke [12]. In the present
study, SO + PG group showed a signiﬁcant reduction in
cerebral infarction area than control or SO group after treat-
m e n t .H o w e v e r ,t h e r ew a sn od i ﬀerence between control and
SO alone, as there were no diﬀerence between combination
group and PG group. This reveals that the cerebral ischemic
reduction eﬀect of PG is superior than SO in cerebral
ischemic rats.
These results suggest that PG plays a role as a neuro-
protector in the combination treatment group. Immuno-
histochemical staining data demonstrated that all treated
drugs suppressed an increase of GFAP-positive cells in the
peripheral area of ischemic infarction, and combination-
treated group was predominant over others. This suggested
that combination with SO and PG may protect against
the infarct expansion through secondary injury caused by
activated astrocytes. Apoptosis is a destructive mechanism
in association with neuronal cell death after an ischemic
stroke. NeuN antigen had widely been used as a marker of
neuronal cell loss [20]. This study showed that the groups
treated with combination of SO and PG showed signiﬁcant
decreased number of TUNEL positive cells compared with
control group or SO alone group. However, treatment with
SO alone did not signiﬁcantly decrease the TUNEL positive
cells compared to control. In the staining of NeuN-positive
cells, all drug-treated groups showed higher number of
NeuN positive cells compared to control group. The group
treated with combination SO and PG showed signiﬁcantly
higher number of NeuN positive cells compared to the
SO treated group. These results suggest that combination
with PG more eﬀectively prevents expansion of astrocyte
and apoptotic neuronal death than SO alone in MCAO
model.
Immunohistochemical staining data showed the de-
creased staining of astrocyte, TUNNEL-positive cell, and
increased staining of NeuN-positive cells on the peri-
infarction area in all the treated groups. However, these
results were predominant in the SO + PG group. These
ﬁndings suggest that the combination group has an anti-
apoptotic eﬀect in cerebral ischemia in rats and inhibition
eﬀect of a glial cell proliferation that results from reactive
gliosis.
Platelet activation and subsequent aggregation play one
of the key roles in the pathogenic mechanisms of ischemic
brain damage [21]. Platelet activation is aggravated after
an ischemic stroke [22, 23], leading to secondary thrombus
formation and further expansion of the cerebral infarction
[24]. Many researchers suggested that SO prevents platelet
aggregation, vascular constriction, and brain edema in acute
cerebral ischemia [6–9]. In the present study, we presumed
that the SO may attribute to the inhibition of postischemic
hypoperfusion and induce the cerebral edema after the
cerebral ischemia/reperfusion via the inhibition of the TXA2
synthesis. But, all of our studies showed that the neuro-
protective eﬀects of PG were superior than SO in MCAO
rats.
5.Conclusion
We have shown that the combination therapy with SO and
PG may provide more of the neuroprotective eﬀects than
monotherapy with SO or PG alone in MCAO stroke rat
models such as reduction of infarct volume and prevention
of gliosis and neuronal cell death. Therefore, the author sug-
gests that the cerebral blood ﬂow increased to the peripheral
area of ischemic zone by SO, and several neuroprotective
eﬀectsofPG makethe additive eﬀect in the cerebralischemic
rats. These results suggested that if these two types of
medicines are simultaneously used in treating patients with
acute cerebral infarction, it could signiﬁcantly improve the
outcome of patients.
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